Expert Interview
Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Ticker(s): PFE, ALPMYInstitution: Parkview Health
- Head of Urologic cancer surgery at Parkview Health.
- Manages 500 patients with non-metastatic hormone sensitive prostate cancer.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
